Healthspan vs. Lifespan

Longevity work is credible only when it distinguishes more years alive from more years lived with preserved function.

Also known as: healthy longevity, healthy life expectancy, HALE, health-adjusted life expectancy

Context

Most longevity claims sound clearer than they are. A clinic can advertise a program that aims to extend life. A supplement company can imply that a pathway is “pro-longevity.” A training plan can be sold as healthspan work. Without a clean distinction between lifespan and healthspan, those claims collapse into a single attractive promise: live longer.

Lifespan is the simpler term. For an individual, it is the duration from birth to death. For a population, the usual public-health proxy is life expectancy: the average number of years a person would be expected to live if current mortality rates applied across life. Healthspan is harder. It means the portion of life spent in good enough health to function, participate, think, move, and live without major disease or disabling limitation.

The difficulty is that “good enough health” isn’t a single thing. A 2025 systematic review found 113 primary definitions of healthspan across the literature, with definitions variously tied to absence of chronic disease, absence of disability, preserved performance, or subjective quality of life (Masfiah et al., 2025). That doesn’t make the term useless. It means every serious use of it has to say what is being counted.

Problem

The longevity field keeps mixing three questions that should stay separate: how long people live, how long they live without substantial disease or disability, and how long they preserve the capacities they personally care about. The first question is demographic. The second is public-health and clinical. The third is partly personal, because a powerlifter, a surgeon, a parent with young children, and a retired teacher may care about different thresholds of function.

The confusion matters because interventions can look better or worse depending on which question is being asked. Intensive late-life medical care may extend survival while adding years with disability. Better blood-pressure control may extend both life expectancy and healthy life expectancy. A biological-age test may report a younger estimate without proving that the person will live more years free of disease. If the endpoint is vague, the claim can’t be evaluated.

Forces

• Longer survival can expose more years of chronic disease if morbidity is not delayed.
• Healthspan is attractive because it sounds patient-centered, but the term is still operationally inconsistent.
• Population measures such as health-adjusted life expectancy are comparable, but they flatten individual goals and disability weights into one number.
• Personal function matters, yet self-defined “I feel great” healthspan can become evidence-free wellness prose.
• The interventions most likely to improve healthspan are often boring compared with frontier therapies.

Solution

Separate the lifespan claim from the healthspan claim every time. Ask first whether a practice is being claimed to increase survival, delay disease and disability, preserve function, or improve a proxy marker. Then ask which measure supports that claim.

Use four terms precisely:

The most usable public-health proxy is HALE: healthy life expectancy, also called health-adjusted life expectancy. WHO reports both life expectancy and HALE. In 2019, before the COVID-19 reversal, global life expectancy at birth was 73.1 years and HALE was 63.5 years; life expectancy had gained 6.4 years since 2000, while HALE had gained 5.3 years (WHO Global Health Observatory, 2026). By 2021, after the pandemic shock, WHO estimated global life expectancy at 71.4 years and HALE at 61.9 years, roughly a 9.5-year gap (WHO, 2024).

For an individual reader, the translation is practical: don’t treat a lower epigenetic age, better VO2max, improved ApoB, or cleaner sleep score as “extended healthspan” unless it is tied to a plausible chain of evidence. The strongest chain runs from an intervention to a validated risk factor, from the risk factor to disease or disability incidence, and from there to healthier years. A weaker chain may still be worth acting on, but it should be named as weaker.

Evidence

Evidence tier: Observational (human, large). The healthspan-lifespan gap is measured from population data, not randomized trials. Its strongest evidence comes from life tables, burden-of-disease estimates, disability weights, and longitudinal surveillance.

The most direct recent estimate is Garmany and Terzic’s 2024 analysis of 183 WHO member states. Using WHO Global Health Observatory data through 2019, they found that the global healthspan-lifespan gap widened from 8.5 years in 2000 to 9.6 years in 2019, a 13% increase. The United States had the largest country gap in that analysis at 12.4 years, with noncommunicable disease burden driving much of the difference (Garmany and Terzic, 2024).

This fits the older compression-of-morbidity frame. James Fries argued in 1980 that the public-health goal should not be indefinite survival with a longer tail of infirmity, but postponement of chronic illness so that morbidity is compressed closer to the end of life (Fries, 1980). Eileen Crimmins later summarized the uncomfortable state of the evidence: life expectancy rose substantially over the twentieth century, but broad compression of morbidity had not clearly followed, partly because treatment lets people live longer with disease (Crimmins, 2015).

The strongest counterweight is definitional. Masfiah and colleagues’ 2025 review found that healthspan definitions are not standardized, and many operationalizations count different endpoints. One study may define healthspan as years without major chronic disease. Another may use disability-free survival. A third may include quality of life. Those are related, but they aren’t interchangeable.

How It Plays Out

A reader evaluating a longevity clinic should ask what the clinic means by “healthspan.” If the answer is a bundle of tests, the claim is still incomplete. Full-body MRI, coronary calcium scoring, ApoB, VO2max, and epigenetic clocks can all inform risk, but a test panel isn’t a healthspan result. It is a measurement layer.

A reader evaluating a lifestyle intervention should ask whether the endpoint is disease, disability, function, or a proxy. Resistance training has a clear functional healthspan case because strength, muscle mass, bone density, falls risk, and late-life independence are tightly connected. A supplement that shifts a mechanistic biomarker in mice has a much weaker case, even if the sales page uses the same healthspan language.

A reader interpreting population statistics should avoid the easy mistake: higher life expectancy does not automatically mean better aging. Countries with long life expectancy can still carry a wide healthspan-lifespan gap because people survive longer with noncommunicable disease, pain, frailty, cognitive impairment, or disability. In the 2024 JAMA analysis, the largest gaps were concentrated in high-income countries, not in the countries with the shortest lives.

Consequences

Benefits. The distinction prevents false precision. It lets a reader see why lifespan extension, disease-risk reduction, preserved physical capacity, cognitive function, and biological-age estimates are related but not the same. It also keeps frontier claims honest: a therapy can be mechanistically interesting without having shown that it adds healthy years in humans.

It also gives prioritization teeth. If the goal is more healthy years, the base of the stack matters: blood pressure, ApoB, sleep, cardiorespiratory fitness, strength, glucose control, smoking avoidance, social connection, and fall prevention. These don’t look as novel as plasma exchange or gene therapy tourism, but they sit closer to the human evidence.

Liabilities. Healthspan can become a vague prestige word. A company can claim to support healthspan while measuring only a biomarker it sells a product around. A public-health dataset can make healthspan look precise while burying subjective judgments inside disability weights. A reader can also overcorrect, dismissing lifespan as crude when survival is still a hard endpoint that matters.

The better discipline is not to choose one term and discard the other. Use lifespan when the question is survival. Use healthspan when the question is years of preserved function. Use HALE when comparing populations. Use specific outcomes when evaluating an intervention: disease incidence, disability-free survival, grip strength, VO2max, cognitive performance, activities of daily living, or quality-of-life measures. The name earns trust only when the measure follows it.

Related Patterns

Sources

• Crimmins, Eileen M. “Lifespan and Healthspan: Past, Present, and Promise.” The Gerontologist 55, no. 6 (2015): 901-911. https://doi.org/10.1093/geront/gnv130
• Fries, James F. “Aging, Natural Death, and the Compression of Morbidity.” New England Journal of Medicine 303, no. 3 (1980): 130-135. https://doi.org/10.1056/NEJM198007173030304
• Garmany, Armin, and Andre Terzic. “Global Healthspan-Lifespan Gaps Among 183 World Health Organization Member States.” JAMA Network Open 7, no. 12 (2024): e2450241. https://doi.org/10.1001/jamanetworkopen.2024.50241
• Masfiah, Siti, Alfarid Kurnialandi, Johannes Jacobus Meij, and Andrea Britta Maier. “Definitions of Healthspan: A Systematic Review.” Ageing Research Reviews 111 (2025): 102806. https://doi.org/10.1016/j.arr.2025.102806
• World Health Organization. “GHE: Life Expectancy and Healthy Life Expectancy.” Global Health Observatory, accessed May 7, 2026. https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates/ghe-life-expectancy-and-healthy-life-expectancy
• World Health Organization. “COVID-19 Eliminated a Decade of Progress in Global Level of Life Expectancy.” May 24, 2024. https://www.who.int/news/item/24-05-2024-covid-19-eliminated-a-decade-of-progress-in-global-level-of-life-expectancy